CCM
AMPH icon

Cadence Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Cadence Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-27,593
Closed -$517K – 675
2018
Q1 		$517K Buy
27,593
+2,908
+12% +$54.7K 0.03% 500
2017
Q4 		$475K Buy
24,685
+1,782
+8% +$33.3K 0.03% 506
2017
Q3 		$409K Sell
22,903
-16,265
-42% -$268K 0.03% 539
2017
Q2 		$700K Sell
39,168
-23,619
-38% -$375K 0.05% 438
2017
Q1 		$910K Buy
62,787
+38,303
+156% +$602K 0.06% 380
2016
Q4 		$451K Buy
24,484
+544
+2% +$10.6K 0.03% 533
2016
Q3 		$454K Buy
+23,940
New +$435K 0.03% 500

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cadence Capital Management's AMPH Position: Q2 2018 in Review

Cadence Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2018, closing a stake of 27,593 shares — an estimated $517K sold.

Cadence Capital Management first reported a position in AMPH in Q3 2016 and held it in 7 quarters. The position peaked at $910K in Q1 2017. 114 funds tracked by Wall St. Rank hold AMPH as of Q2 2018.

  • Cadence Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Cadence Capital Management sold 27,593 Amphastar Pharmaceuticals shares in Q2 2018, an estimated $517K.
  • Cadence Capital Management first reported a position in Amphastar Pharmaceuticals in Q3 2016 and held it in 7 quarters.
  • Cadence Capital Management's Amphastar Pharmaceuticals position peaked at $910K in Q1 2017.
  • 114 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2018.

Based on Cadence Capital Management's 13F filing for Q2 2018, filed 9 Aug 2018.